<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="USD" hierarchy="1" humanitarian="0" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>SE-0-SE-6-5410017002-GGG-12182</iati-identifier>
  <reporting-org ref="SE-0" secondary-reporter="0" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="SV">WHO Forskningsst&#xF6;d 2016-2019</narrative>
   <narrative xml:lang="EN">WHO Research support 2016-2019</narrative>
  </title>
  <description type="1">
   <narrative xml:lang="SV">Programst&#xF6;d till f&#xF6;ljande forskningsprogram d&#xE4;r V&#xE4;rldsh&#xE4;lsoorganisationen (WHO) agerar v&#xE4;rd: 

i) Alliance for Health Policy and Systems Research, AHPSR eller &quot;the Alliance&quot;;  

ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, HRP; och 

iii) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases,TDR. 

Det f&#xF6;reslagna st&#xF6;det &#xE4;r en forts&#xE4;ttning p&#xE5; tidigare avtal 2016-2017. Anledningen till en avtalsf&#xF6;rl&#xE4;ngning ist&#xE4;llet f&#xF6;r nytt l&#xE4;ngre avtal &#xE4;r att svenska regeringens strategi med WHO g&#xE4;ller &#xE5;ren 2016-2019, och en ny strategi f&#xF6;rv&#xE4;ntas fr&#xE5;n 2020. 

Det totala beloppet &#xE4;r 407,2 miljoner SEK f&#xF6;r perioden 2016 - 2019, varav 199 miljoner SEK avser f&#xF6;rl&#xE4;ngningen 2018-2019.  

St&#xF6;det fr&#xE5;n Sida utg&#xE5;r huvudsakligen som programst&#xF6;d och &#xE4;r d&#xE4;rf&#xF6;r av s&#xE4;rskild betydelse f&#xF6;r programmen d&#xE5; s&#xE5;dant st&#xF6;d &#xE4;r en f&#xF6;ruts&#xE4;ttning f&#xF6;r den flexibilitet som kr&#xE4;vs f&#xF6;r att kunna svara mot nya forskningsbehov och st&#xF6;dformer. Under den f&#xF6;reslagna avtalsperioden f&#xF6;resl&#xE5;s Sida att bidra med cirka 23% av AHPSR:s totala budget, cirka 11% av HRP:s dito, respektive cirka 27% av TDR:s dito. Sverige &#xE4;r b&#xE5;de historiskt och volymm&#xE4;ssigt forskningsprogrammens viktigaste givare. 

Sida har l&#xE5;ng erfarenhet, sedan mitten av 1970-talet av st&#xF6;d till WHO:s forskning i form av s&#xE5;v&#xE4;l speciella frist&#xE5;ende forskningsprogram som separata forskningsprojekt. Erfarenheterna visar att WHO har f&#xF6;rm&#xE5;ga att engagera ledande forskare p&#xE5; global niv&#xE5; f&#xF6;r fattigdomsrelaterade h&#xE4;lsofr&#xE5;gor och att i synnerhet de frist&#xE5;ende programmen f&#xF6;rm&#xE5;r anpassa sin verksamhet till f&#xF6;r&#xE4;ndringar i omv&#xE4;rlden och att inta ledande roller inom den globala forskningsagendan. Erfarenheten har ocks&#xE5; visat att de forskningsresultat som produceras inom programmen f&#xE5;r global spridning i kraft av WHO:s normativa (f&#xF6;reskrivande) mandat, vilket &#xE4;r bindande f&#xF6;r alla medlemsstater. 

Den &#xF6;vergripande bed&#xF6;mningen av de tre programmen &#xE4;r att de &#xF6;ver l&#xE5;ng tid visat resultat i niv&#xE5; med uppsatta m&#xE5;l. Under 2016 har f&#xF6;ljande resultat rapporterats fr&#xE5;n programmen (resultat fr&#xE5;n 2017 kommer att rapporteras f&#xF6;rst i b&#xF6;rjan av 2018): 

Urval av resultat fr&#xE5;n HRP&apos;s insatser 2016:
1) Inom ramen f&#xF6;r HRP utvecklades nya uppdaterade rekommendationer p&#xE5; anv&#xE4;ndning av preventivmedel 
2) HRP avslutade en studie som visar att preventivimplantatet (ENG-implantat), som f&#xF6;r n&#xE4;rvarande &#xE4;r godk&#xE4;nd f&#xF6;r upp till tre &#xE5;rs anv&#xE4;ndning, kan vara effektiv i upp till fem &#xE5;r. Den ut&#xF6;kade anv&#xE4;ndningsperioden f&#xF6;r ENG-implantatet kan f&#xF6;rb&#xE4;ttra skyddet fr&#xE5;n oavsiktlig graviditet f&#xF6;r anv&#xE4;ndare och minska kostnader och spara resurser f&#xF6;r h&#xE4;lsosystem.
3) HRP st&#xF6;dde utvecklingen av ett nytt verktyg f&#xF6;r ett standardiserat system f&#xF6;r klassificering d&#xF6;df&#xF6;dda sp&#xE4;dbarn och neonatala d&#xF6;dsfall. Det g&#xF6;r det m&#xF6;jligt f&#xF6;r l&#xE4;nder att koppla d&#xF6;dsfallen till gravida kvinnors speciella f&#xF6;rh&#xE5;llanden, och identifierar d&#xE4;rmed interventioner som kan f&#xF6;rhindra s&#xE5;dana d&#xF6;dsfall. 
4) HRP utvecklade en ny guide: Graviditetshantering i samband med Zika
virusinfektion. Denna v&#xE4;gledning rekommenderar &#xE5;tg&#xE4;rder f&#xF6;r att f&#xF6;rebygga Zika virusinfektion, f&#xF6;rlossningsv&#xE5;rd och hantering av kvinnor med Zika-infektion, inklusive interventioner till att hantera potentiella komplikationer under graviditeten och ta hand om alla gravida kvinnor som bor i Zika-drabbade omr&#xE5;den, i syfte att optimera h&#xE4;lsoutfall f&#xF6;r m&#xF6;drar och nyf&#xF6;dda.
5) HRP lanserade den f&#xF6;rsta globala databasen &#xF6;ver abortlagstiftning, politik, h&#xE4;lsa
standarder och riktlinjer med data fr&#xE5;n 197 l&#xE4;nder, inklusive 213 jurisdiktioner, &#xE5;r 2017

Urval av resultat fr&#xE5;n programmet Alliance 2016:
1) Lanseringen av de f&#xF6;rsta samh&#xE4;llsutm&#xE4;rkelserna f&#xF6;r h&#xE4;lsosystemsforskning, tillsammans med Health Systems Global (HSG), som erk&#xE4;nner forskares och beslutsfattares bidrag till omr&#xE5;det f&#xF6;r HPSR och evidensbaserad policy-making.
2) Alliance&#x2019;s fj&#xE4;rde flaggskeppsrapport &#x201D; Open mindsets: Participatory leadership for health&#x201D; lanserades
3) Utbildningsverktyg lanserades av AHPSR under 2016: HSPR-databasen, online kurser om systemt&#xE4;nkande inom folkh&#xE4;lsan, och inr&#xE4;ttning av initiativet Global Evidence Synthesis (GESI)
4) Lansering av implementeringsforskningsstudie om elektrifiering av h&#xE4;lsofaciliteter (med PAHO)

Urval av resultat fr&#xE5;n fr&#xE5;n programmet TDR 2016:
1) Tillv&#xE4;gag&#xE5;ngss&#xE4;tt som bygger motst&#xE5;ndskraft mot klimatf&#xF6;r&#xE4;ndringar - fokusera p&#xE5; de mest utsatta befolkningarna i Afrika. Resultaten inkluderar utveckling av evidensbaserade beslutsst&#xF6;dprocesser, samt verktyg f&#xF6;r fyra sjukdomar. 
2) Landberedskap f&#xF6;r sjukdomsutbrott, inklusive dengue, zika och chikungunya
3) F&#xF6;rb&#xE4;ttrade v&#xE5;rdalternativ f&#xF6;r sm&#xE5;barn med malaria genom demonstrationer av hur antalet sv&#xE5;ra malariafall minskade avsev&#xE4;rt i de deltagande l&#xE4;nderna. Snabb diagnos, oral artemisinin kombinationsbehandling och rektal artesunate behandling f&#xF6;r sv&#xE5;r malaria i 172 avl&#xE4;gsna byar med h&#xF6;g malariab&#xF6;rda.

En ny generaldirekt&#xF6;r f&#xF6;r WHO tilltr&#xE4;dde i juli 2017, Dr Tedros Adhanom Ghebreyesus, och med honom har WHO en ny grupp i ledningen (2 Deputy Director-Generals och 11 Assistant Director-Generals). Totalt sett best&#xE5;r ledningen av 60% kvinnor. Dr Tedros har redan satt ig&#xE5;ng f&#xF6;r&#xE4;ndringar inom WHO, f&#xF6;rst i form av en &#xF6;ppen konsultation f&#xF6;r att ta fram n&#xE4;sta &quot;Generella Arbetsplan&quot; 2019-2023. 

De tre forskningsprogrammen leds av egna styrgrupper d&#xE4;r givarna representeras, vilka beslutar om forskningsprogrammens strategier, arbetsplaner och budgetar. HRP fokuserar p&#xE5; de relevanta globala strategierna, som Global Strategy for Women&#x2019;s, Children&#x2019;s and Adolescents&#x2019; Health (Global Strategy) och Sustainable Development Goals (SDGs), f&#xF6;r att genom forskning f&#xF6;rb&#xE4;ttra sexuell och reproduktiv h&#xE4;lsa och att s&#xE4;kerst&#xE4;lla m&#xE4;nskliga r&#xE4;ttigheter runtom i v&#xE4;rlden. 

TDR har en ny strategi 2018-2023 som kallas &#x201D;Building the Science of Solutions&#x201D;. Strategin st&#xF6;djer TDR&#x2019;s vision att st&#xE4;rka h&#xE4;lsa och v&#xE4;lbefinnande av m&#xE4;nniskor med fattigdomsrelaterade infektionssjukdomar genom forskning och innovation. 

Alliance f&#xF6;ljer en strategisk plan 2016-2020 som kallas &#x201D;Investing in Knowledge for Resilient Health Systems&#x201D; med fyra strategiska m&#xE5;l: &#x201D;provision of a unique forum for the health policy and systems research community; supporting institutional capacity for the conduct and uptake of health policy and systems research; stimulating the generation of knowledge and innovations to nurture learning and resilience in health systems, and increasing the demand for and use of knowledge for strengthening health systems&#x201D;. 

Programmet AHPSR kommer s&#xE5;ledes under avtalsperioden att fortsatt finansiera forskning om h&#xE4;lsosystem och policies som bidrar till att fattiga l&#xE4;nder kan nyttja sina resurser f&#xF6;r h&#xE4;lsosektorn p&#xE5; ett s&#xE5; effektivt som m&#xF6;jligt. HRP:s inriktning f&#xF6;r den kommande tv&#xE5;-&#xE5;rsperioden innefattar forskning om ungdomars sexuella och reproduktiva h&#xE4;lsa och f&#xF6;rb&#xE4;ttrad m&#xF6;drav&#xE5;rd under s&#xE5;v&#xE4;l graviditet som efter f&#xF6;rlossning. TDR:s aktiviteter kommer under avtalsperioden att ha tyngdpunkten p&#xE5; forskning om hinder f&#xF6;r effektivt genomf&#xF6;rande av befintliga kontrollprogram f&#xF6;r olika infektionssjukdomar s&#xE5;som malaria, tuberkulos och olika tarmparasiter.</narrative>
   <narrative xml:lang="EN">The proposed intervention is programme support for the period 2016 - 2019 to three research programmes hosted by the World Health Organisation (WHO): 

i) Alliance for Health Policy and Systems Research, AHPSR or &quot;the Alliance&quot;;  

ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction, HRP; and 

iii) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases, TDR. 

The proposed support is an extension of the ongoing Agreement 2016-2017. The reason for not preparing a new agreement is that the framework agreement between Sweden/Sida and WHO lasts until 2019. The total contribution 2016-2019 is 407,2 million SEK, including 199 million SEK for the biennium 2018 - 2019.   

The Sida support is mainly disbursed as programme support and is therefore of particular importance to the programmes as this enables them to develop their programmes to address emerging research needs and types of support. The share of undesignated support of the total budget from all funders to the programmes were for AHPSR 78% (2015), for HRP 60% (2014) and for TDR 81% (2014). Sida&apos;s contribution during the proposed agreement period is estimated to 23% of AHPSR&apos;s overall budget, approx. 11% of the HRP&apos;s ditto, respectively 27% of TDR&apos;s ditto.    

Sida has extensive experience, since the mid-1970s of support to WHO for research carried out either by special research programmes or as separate research projects. Experience shows that the WHO has the ability to engage leading researchers for poverty related health issues and that the stand-alone research programmes are able to adapt to changes in the research environment and take leading role in the global research agenda. Experience has also shown that the research results produced in the programs are spread globally as a result of the WHO normative mandate. 

The overall assessment is that the three programmes over time have proven results in line with targets. For the biennium 2016-2017 some of the results reported are summarized below: 

Selected results HRP 2016-2017:
1) HRP developed new updated recommendations on the use of contraceptives and fertility care asssesment guide that was piloted in Sudan and Zambia. 
2) HRP concluded a study showing that the contraceptive implant (ENG implant), currently approved for up to three years of use, can be effective for up to five years. The extended use period of the ENG implant can improve protection from inadvertent pregnancy for users and reduce costs and save resources for health systems.
3) HRP supported the development of a new tool for a standardized system for the classification of dead born infants and neonatal deaths. Pilot collection was completed for Nigeria and Uganda.
4) HRP developed a new guide: Pregnancy management in conjunction with Zika virus infection that recommends measures to prevent and manage Zika virus infection.
5) Inititated randomized control trial to determine best pain control medicament for first trimester medical abortion in Nepal, Vietnam and South Africa
6) In 2017 HRP launched the first global database on abortion law, politics, health Standards and Guidelines with data from 197 countries, including 213 jurisdictions.

Selected results from the AHPSR 2016:
1) The launch of the first social awards for health systems research, together with Health Systems Global (HSG), which acknowledges the contributions of researchers and decision makers to the HPSR area and evidence-based policy making.
2) Alliance&apos;s fourth flagship report &quot;Open mindset: Participatory leadership for health&quot; was launched
3) Training Tools Launched by AHPSR in 2016: The HSPR Database, Online Courses on System Thinking in Public Health, and the establishment of the Global Evidence Synthesis (GESI) initiative.
4) Launch of Implementation Research Study on Electrification of Health Facilities (with PAHO)

Selected results from TDR 2016:
1) Climate Change Modalities - Focus on the most vulnerable populations in Africa. The results include the development of evidence-based decision support processes, as well as tools for four diseases.
2) Land contingency for disease outbreaks, including dengue, zika and chikungunya
3) Improved care options for young children with malaria through demonstrations of how the number of severe malaria cases decreased significantly in the participating countries. Rapid diagnosis, oral artemisinin combination therapy and rectal artesunate treatment for severe malaria in 172 remote villages with high malaria incidence.

During the upcoming proposed agreement period AHPSR will continue to support research on health systems and policies which assist low-income countries to use their health sector resources as efficiently as possible. HRP focus for the coming two-year period, includes research on young people&apos;s sexual and reproductive health and improving maternal health during pregnancy and in postpartum. TDR&apos;s activities during the upcoming agreement period will have an emphasis on research into barriers to effective implementation of existing monitoring programmes for various infectious diseases such as malaria, tuberculosis and various intestinal parasites.

A new Director-General of the WHO came in place in July 2017, Dr. Tedros Adhanom Ghebreyesus, and with him, the WHO has a new management (2 Deputy Director-Generals and 11 Assistant DGs). In total, the management consists of 60% women. Dr Tedros has already initiated changes within the WHO, first in the form of an open consultation to develop the next General Work Plan 2019-2023.

The three research programs have their own boards that approve the programs&apos; strategies, work plans and budgets. 

HRP focuses on relevant global strategies, such as the Global Strategy for Women, Children&apos;s and Adolescents&apos; Health (SDGs), through research to improve sexual and reproductive health and to ensure human rights around the world. HRP activities and plans are guided by the &quot;HRP Portfolio Review Process Report&quot;, a process established in 2016 to guide priority areas for work that take into consideration emerging issues and the HRP capacity to respond to them.

TDR has a new strategy 2018-2023 called &quot;Building the Science of Solutions&quot;. The strategy supports TDR&apos;s vision that &#x201C;the health and well-being of people burdened by infectious diseases of poverty is improved through research and innovation,&#x201D; and its mission &#x201C;to support effective and innovative global health research, through strengthening the research capacity of disease-affected countries, and promoting the translation of evidence into interventions that reduce the burden of infectious diseases and build resilience in the most vulnerable populations&#x201D;. 

Alliance follows a strategic plan 2016-2020 called &quot;Investing in Knowledge for Resilient Health Systems&quot; with four strategic objectives: &quot; provision of a unique forum for the health policy and systems research community; supporting institutional capacity for the conduct and uptake of health policy and systems research; stimulating the generation of knowledge and innovations to nurture learning and resilience in health systems, and increasing the demand for and use of knowledge for strengthening health systems. The Alliance plans are aligned with WHO&apos;s agenda and framework for Health Systems Strengthening considered pivotal for the accomplishment of the SDG Universal Health Coverage.&quot;.

Thus, during the contract period, the AHPSR program will continue to fund research on health systems and policies that help poor countries utilize their resources for the health sector as efficiently as possible. HRP&apos;s focus on the next two-year period includes research on young people&apos;s sexual and reproductive health and improved maternity care during pregnancy and postnatal care. TDR activities will during the contract period focus on research on barriers to effective implementation of existing control programs for various infectious diseases such as malaria, tuberculosis and various intestinal parasites.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">Swedish support to the three WHO-hosted research programmes TDR, HRP and AHPSR is well aligned with the&#xA0;Strategy for research cooperation and research in development cooperation 2015 &#x2013; 2021&#xA0;covering research of relevance to low-income countries and regions, research capacity building and promotion of research that, through innovation, can contribute to poverty reduction and sustainable development.
Full names and main purposes of the WHO-based research programmes are:
i) The UNICEF-UNDP-World Bank-WHO Special Programme for Research and Training in Tropical Diseases (TDR):&#xA0;TDR helps facilitate, support and influence efforts to combat diseases of poverty, with the mission to &quot;support effective and innovative global health research, through strengthening the research capacity of disease-affected countries, and promoting the translation of evidence into interventions that reduce the burden of infectious diseases and build resilience in the most vulnerable populations&quot;. TDR main areas are i) Research for policy; ii) Research for implementation; iii) Research for innovation; and iv) Research for integrated approaches.
ii) The UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP):&#xA0;HRP is the main instrument within the United Nations system for research in human reproduction, bringing together policy-makers, scientists, health care providers, clinicians, consumers and community representatives to identify and address priorities for research to improve sexual and reproductive health. The mission of HRP is &quot;the attainment of all people of the highest possible level of sexual and reproductive health. HRP strives for a world where all women&#x2019;s and men&#x2019;s rights to enjoy sexual and reproductive health are promoted and protected, and all women and men, including adolescents and those who are underserved and marginalized, have access to sexual and reproductive health information and services&quot;.
iii) Alliance for Health Policy and Systems Research (AHPSR):&#xA0;AHPSR work to improve the health of those in low- and middle-income countries by supporting the generation and use of evidence that strengthens health systems. Together with organizations around the world, the AHPSR aims to i) provide a unique forum for the health policy and systems research community; ii) support institutional capacity for the conduct and uptake of health policy and systems research; iii) stimulate the generation of knowledge and innovations to nurture learning and resilience in health systems; and iv) increase the demand for and use of knowledge for strengthening health systems.
In brief, TDR focuses on infectious diseases of poverty, HRP on sexual and reproductive health and rights, and AHPSR on health policy and systems.
Sida is a long-term supporter of TDR, HRP (over 40 years) and AHPSR (over 20 years) and has major insights into the programmes.</narrative>
  </description>
  <participating-org ref="SE-0" role="1" type="10">
   <narrative xml:lang="EN">Sweden</narrative>
  </participating-org>
  <participating-org ref="SE-6" role="3" type="10">
   <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
  </participating-org>
  <participating-org ref="41143" role="2">
   <narrative xml:lang="EN">WHO/World Health Organization</narrative>
  </participating-org>
  <participating-org ref="41143" role="4" type="40">
   <narrative xml:lang="EN">World Health Organisation - core voluntary contributions account</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2016-10-18" type="1"></activity-date>
  <activity-date iso-date="2016-10-18" type="2"></activity-date>
  <activity-date iso-date="2020-06-30" type="3"></activity-date>
  <activity-date iso-date="2020-06-30" type="4"></activity-date>
  <contact-info>
   <organisation>
    <narrative xml:lang="EN">Swedish International Development Cooperation Agency</narrative>
   </organisation>
   <telephone>+46 8 698 50 00</telephone>
   <email>sida@sida.se</email>
   <website>www.sida.se</website>
   <mailing-address>
    <narrative xml:lang="EN">Valhallav&#xE4;gen 199, 105 25 Stockholm, Sweden</narrative>
   </mailing-address>
  </contact-info>
  <recipient-region code="998" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Developing countries, unspecified</narrative>
  </recipient-region>
  <sector code="121" percentage="100" vocabulary="2">
   <narrative xml:lang="EN">Health, General</narrative>
  </sector>
  <sector code="12182" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">Medical research</narrative>
  </sector>
  <tag code="3.7" vocabulary="3">
   <narrative xml:lang="EN">3.7 - By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes.</narrative>
   <narrative xml:lang="SV">3.7 - Senast 2030 s&#xE4;kerst&#xE4;lla att alla har tillg&#xE5;ng till sexuell och reproduktiv h&#xE4;lsov&#xE5;rd, inklusive familjeplanering, information och utbildning, och att reproduktiv h&#xE4;lsa integreras i nationella strategier och program.</narrative>
  </tag>
  <tag code="3.B" vocabulary="3">
   <narrative xml:lang="SV">3.b - St&#xF6;dja forskning om och utveckling av vaccin och l&#xE4;kemedel mot de smittsamma och icke-smittsamma sjukdomar som i f&#xF6;rsta hand drabbar utvecklingsl&#xE4;nder. S&#xF6;rja f&#xF6;r tillg&#xE5;ng till ekonomiskt &#xF6;verkomliga grundl&#xE4;ggande l&#xE4;kemedel och vaccin, i enlighet med Doha-deklarationen om TRIPS-avtalet och folkh&#xE4;lsa, i vilken det bekr&#xE4;ftas att utvecklingsl&#xE4;nderna har r&#xE4;tt att fullt ut utnyttja den flexibilitet som avtalet om handelsrelaterade aspekter av immaterialr&#xE4;tter erbjuder f&#xF6;r att skydda folkh&#xE4;lsan och, framf&#xF6;r</narrative>
   <narrative xml:lang="EN">3.b - Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public healt</narrative>
  </tag>
  <tag code="5.6" vocabulary="3">
   <narrative xml:lang="EN">5.6 - Ensure universal access to sexual and reproductive health and reproductive rights as agreed in accordance with the Programme of Action of the International Conference on Population and Development and the Beijing Platform for Action and the outcome documents of their review conferences.</narrative>
   <narrative xml:lang="SV">5.6 - S&#xE4;kerst&#xE4;lla allm&#xE4;n tillg&#xE5;ng till sexuell och reproduktiv h&#xE4;lsa och reproduktiva r&#xE4;ttigheter i enlighet med &#xF6;verenskommelserna i handlingsprogrammet fr&#xE5;n den internationella konferensen om befolkning och utveckling, Pekingplattformen samt slutdokumenten fr&#xE5;n respektive &#xF6;versynskonferenser.</narrative>
  </tag>
  <policy-marker code="5" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention on Biological Diversity</narrative>
  </policy-marker>
  <policy-marker code="8" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Convention to Combat Desertification</narrative>
  </policy-marker>
  <policy-marker code="7" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Adaptation</narrative>
  </policy-marker>
  <policy-marker code="6" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid Targeting the Objectives of the Framework Convention on Climate Change - Mitigation</narrative>
  </policy-marker>
  <policy-marker code="2" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Aid to Environment</narrative>
  </policy-marker>
  <policy-marker code="11" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disability</narrative>
  </policy-marker>
  <policy-marker code="10" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Disaster Risk Reduction(DRR)</narrative>
  </policy-marker>
  <policy-marker code="1" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Gender Equality</narrative>
  </policy-marker>
  <policy-marker code="3" significance="1" vocabulary="1">
   <narrative xml:lang="EN">Participatory Development/Good Governance</narrative>
  </policy-marker>
  <policy-marker code="9" significance="2" vocabulary="1">
   <narrative xml:lang="EN">Reproductive, Maternal, Newborn and Child Health (RMNCH)</narrative>
  </policy-marker>
  <policy-marker code="4" significance="0" vocabulary="1">
   <narrative xml:lang="EN">Trade Development</narrative>
  </policy-marker>
  <collaboration-type code="1"></collaboration-type>
  <default-flow-type code="10"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="B03" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">2582831.765324607</value>
  </budget>
  <budget>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">3170703.1707031704</value>
  </budget>
  <budget>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">6443892.110834944</value>
  </budget>
  <budget>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">1353652.217134276</value>
  </budget>
  <planned-disbursement>
   <period-start iso-date="2016-01-01"></period-start>
   <period-end iso-date="2016-12-28"></period-end>
   <value currency="USD" value-date="2016-01-01">2582831.7653246084</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2017-01-01"></period-start>
   <period-end iso-date="2017-12-28"></period-end>
   <value currency="USD" value-date="2017-01-01">3170703.1707031704</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2018-01-01"></period-start>
   <period-end iso-date="2018-12-28"></period-end>
   <value currency="USD" value-date="2018-01-01">6443892.110834945</value>
  </planned-disbursement>
  <planned-disbursement>
   <period-start iso-date="2019-01-01"></period-start>
   <period-end iso-date="2019-12-28"></period-end>
   <value currency="USD" value-date="2019-01-01">1353652.2171342764</value>
  </planned-disbursement>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-03-28"></transaction-date>
   <value currency="USD" value-date="2016-03-28">1986793.6656343131</value>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-10-18"></transaction-date>
   <value currency="USD" value-date="2016-10-18">13790685.443814</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2016-12-28"></transaction-date>
   <value currency="USD" value-date="2016-12-28">596038.0996902939</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-12-28"></transaction-date>
   <value currency="USD" value-date="2017-12-28">3170703.1707031704</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-06-28"></transaction-date>
   <value currency="USD" value-date="2018-06-28">3797293.565313449</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2018-11-28"></transaction-date>
   <value currency="USD" value-date="2018-11-28">2646598.545521495</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-01-28"></transaction-date>
   <value currency="USD" value-date="2019-01-28">359563.8701762921</value>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2019-06-28"></transaction-date>
   <value currency="USD" value-date="2019-06-28">994088.3469579839</value>
  </transaction>
  <result aggregation-status="0" type="2">
   <title>
    <narrative xml:lang="EN">Results achieved</narrative>
    <narrative xml:lang="SV">Uppn&#xE5;dda resultat</narrative>
   </title>
   <description>
    <narrative xml:lang="EN">During the past phase of support, all three programmes have achieved their objectives and produced many relevant results.&#xA0;The three research programmes have shown good capacity to achieve the objectives of the interventions, and show active learning and adapting to a constantly changing environment. In addition, they have an increased collaboration amongst the programmes both at the leadership level and at the activity level. The programmes can learn from each other in areas such as capacity strengthening initiatives, innovation and implementation research.&#xA0;
An unexpected result from the recent years is the establishment of WHO Science Division, where all three programmes actively participate. They share experiences both in between&#xA0;the programmes, but also with other parts of WHO and strengthen&#xA0;research across the organisation. Another result is the increased collaboration with co-sponsors (i.e. Unicef&#xA0;and UNDP) which increases the impact of the programmes as well as its efficiency in budgetary terms. This is to be expected, although has proved&#xA0;difficult&#xA0;to achieve. A less positive development has been the increasing reluctance to SRHR&#xA0;issues of certain&#xA0;countries, especially with regards to safe abortion and comprehensive sexual education, which is a challenge especially for HRP. The development and success of the Social Innovation in Health Initiative&#xA0;of TDR&#xA0;is an unexpected result during the last phase, providing a potential platform for innovative approaches for all three programmes.&#xA0;
An extensive description of results is to be found in the annual statements and the recent appraisal of the new support. Some recent selected results are as follows:
TDR:
- 178 master&#x2019;s students were trained 2015-2018 through postgraduate training schemes focused on implementation research
- The 2018 performance measurements confirmed that TDR&#x2019;s sustained efforts towards improving gender and socio-economic equity are yielding results: the proportion of women among recipients of grants and contracts increased to 47%, and the average amount of a grant was identical for women and men. In addition, 44% of first authors of TDR-supported publications and 57% of expert advisers were women.
- TDR&#x2019;s sustained focus on low- and middle-income countries is reflected in the fact that 83% of grants and contracts went to institutions and individuals in LMICs and 73% of publications had a first author from an LMIC. From the 222 peer-reviewed publications supported by TDR in 2018, 57% specifically addressed vulnerable populations, gender and disabilities.
- TDR expanded training of researchers in the regions through TDR&#x2019;s regional training centres, which have trained in total almost 2000 researchers in short courses, and they expanded the training reach through a Massive Open Online Course on Implementation Research to approximately 1600 researchers in 2018.
- In 2018-2019, TDR developed over 20 new or improved solutions, tools and implementation strategies in collaboration with country institutions and/or WHO disease control programmes. These tools are aligned with the needs and priorities of disease endemic countries, to support translation of evidence to policy and practice. This way, by early engaging with local and national stakeholders in countries, the sustainable integration of TDR&#x2019;s outputs in countries&#x2019; health systems is greatly facilitated.
- The United States Food and Drug Administration&#x2019;s approval of moxidectin for the treatment of river blindness will likely improve the health of millions of people in sub-Saharan Africa and speed up the elimination of this debilitating disease. It is the first new treatment for river blindness in 30 years, and TDR was instrumental in the development. In addition to supporting TDR, Sida contributed to GHIF through Guarantees, which made this progress possible.
- An improved Early Warning and Response System (EWARS) tool has increased country capacity to detect and respond to outbreaks of dengue fever. The EWARS tool has been shown to be equally successful in predicting outbreaks of Zika and chikungunya in Colombia and Mexico, and will be expanded to other regions and arboviral vector-borne diseases.
TDR has several interesting projects connecting health to environment and climate change, such as the development of malaria-specific, trypanosomiasis-specific and schistosomiasis-specific tools aimed at increasing population resilience to climate change.
HRP:
- Research on SRHR in health emergencies increased last years, including mental health of adolescent girls.
- Research on Comprehensive Sexual Education has grown substantially, including implementation research.
- Heat-stable carbetocin (used to prevent post-partum haemorrhage) is now available at a similar price as oxytocin and accessible in 90+ countries.
- It was found that 28% of maternal deaths (excluding those related to abortion) are due to pre-existing medical conditions (such as diabetes, malaria), and 27% are due to severe bleeding. One reason is the alarming increase of caesarean section, many unnecessary. 2018, HRP provided evidence for guidance on interventions to decrease unnecessary caesarean sections.
- HRP launched the WHO, UN Human Rights and UN Women interagency statement calling for the elimination of so-called &#x201C;virginity-testing&#x201D;, which has no scientific or clinical basis and is a violation of the human rights of girls.
- In 2019 the Evidence for Contraceptive Options and HIV Outcomes (ECHO) study was finalized. HRP was leading these efforts, and Sida provided extra funds to HRP&#xA0;to keep the normative focus. Designed to provide high-quality evidence to help women at high risk of HIV make informed choices about contraception, the ECHO Study compared the risk of HIV acquisition among women randomized to the progestin-only depot-medroxyprogesterone acetate, given by intramuscular injection (DMPA-IM); a non-hormonal copper intrauterine device (copper IUD); and a progestin-based implant containing the hormone levonorgestrel (LNG implant). The study found no substantial difference in HIV risk among the 7,829 African women who were randomly assigned to use one of three highly effective methods of contraception.
The study also showed a high HIV incidence among study participants, which highlights the need for more aggressive efforts to prevent HIV and for integration of HIV prevention in efforts of contraception use and control of sexually transmitted infections, as previously efforts are taking place in silos.
- In 2018-2019 additional funding from Unit for Global Social Development were used for the so-called &#x201C;combipack project&#x201D;. Medical abortion using a combination of mifepristone and misoprostol has the potential to expand access to safe abortion. The project has resulted in an analysis of the production costs, the addition of the combipack on the list of essential care lists, a decrease in bulk price from 11.56 to 3.75 USD. Pilot testing to increase access is ongoing in seven countries. A great result is that in November 2019 WHO prequalified this combination mifepristone-misoprostol (combipack) for medical abortion.
AHPSR:
- Many of the research&#xA0;projects supported by the AHPSR&#xA0;respond to questions&#xA0;directly identified by policy-makers in LMICs, using an embedded research&#xA0;model to ensure findings from the projects are used&#xA0;to inform policies and have a real impact on health systems and society. One such is a collaboration&#xA0;with the Ethiopian Ministry&#xA0;of Health and the WHO country office, with 15 ongoing research projects addressing prioritised areas of the ministry.&#xA0;
- AHPSR, UNICEF, Gavi and the Vaccine Alliance supported projects leading to direct impact. One example is vaccination rates in Nigeria, where it increased from 61% to 91% in a few years.
- In 2019, AHPSR&#xA0;worked in 42 countries around the world, provided research grants to more than 250 researchers, of which 60% are female and 26% are early-career researchers.
- 55% of the 44 peer-reviewed journal articles have female lead authors and 38% have lead authors from LMICs.&#xA0;
- In 2019 AHPSR&#xA0;LEAP Forum partners (Learning, Engaging and Advocating for Health&#xA0;Policy and Systems Research) held a side event at the UN General Assembly.</narrative>
   </description>
   <indicator ascending="0" measure="5">
    <title>
     <narrative xml:lang="EN">Not applicable</narrative>
    </title>
    <description>
     <narrative xml:lang="EN">No indicator available - only a description of the activity results is published</narrative>
    </description>
   </indicator>
  </result>
  <crs-add>
   <other-flags code="2" significance="1"></other-flags>
  </crs-add>
  <contribution contributionid="54100170" xmlns="http://sida.se/ns/contribution#"></contribution>
  <strategies xmlns="http://sida.se/ns/strategies#">
   <strategy code="1140102" currency="SEK" strategy-amount="0.0" strategy-end-date="2021-12-31" strategy-start-date="2015-01-01">
    <title>Research cooperation 2015-2021</title>
    <titleSV>Forskningssamarbete 2015-2021</titleSV>
   </strategy>
  </strategies>
 </iati-activity>
</iati-activities>
